Treatment of human T-cell acute lymphoblastic leukemia cells with CFTR inhibitor CFTRinh-172. (November 2019)

• Record Type: Journal Article
• Authors: Liu, Mingfeng; Liao, Huijuan; Chen, Yan; Lin, Ziyuan; Liu, Yanyan; Zhang, Xiaohu; Chan, Hsiao Chang; Sun, Huaqin
• Is Part Of: Leukemia research. Volume 86(2019)
• Publication Date: 2019-11
• Subjects: CFTR -- CFTRinh-172 -- Human T-cell acute lymphoblastic leukemia -- Treatment; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2019.106225
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: CFTR inhibitor CFTR-inh172 inhibits human T-ALL cells in vitro. CFTR-inh172 induces alteration of apoptosis and proliferation gene expression. Potential of CFTR-inh172 in human T-ALL treatment. Abstract: Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia. Here, we show that CFTR inhibitor CFTR-inh172 possesses ability to inhibit human T-cell acute lymphoblastic leukemia cells. In detail, CFTR-inh172 inhibited cell proliferation, promoted apoptosis and arrested the cell cycle in human T-cell acute lymphoblastic leukemia cell CCRF-CEM, JURKAT and MOLT-4. Furthermore, transcriptome analysis reveals that CFTR-inh172 induces significant alteration of gene expression related to apoptosis and proliferation. These findings demonstrate the potential of CFTR inhibitor CFTR-inh172 in human T-cell acute lymphoblastic leukemia treatment.